What the ADA now says is that incretin-based therapies and/or metabolic surgery should be considered in adultswith type 1 ...
The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results